<DOC>
	<DOCNO>NCT00171990</DOCNO>
	<brief_summary>This phase III , multicenter , randomize , double-blind , parallel-group study compare efficacy safety two-day treatment famciclovir ( 500 mg load dose follow 250 mg 12-hourly ) standard five-day treatment famciclovir ( 125 mg 12-hourly ) patient active recurrent genital herpes . This study recruit patient United States .</brief_summary>
	<brief_title>Efficacy Safety Oral Famciclovir Patients With Active Recurrent Genital Herpes</brief_title>
	<detailed_description />
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Famciclovir</mesh_term>
	<mesh_term>2-Aminopurine</mesh_term>
	<criteria>Diagnosis genital herpes Had least 2 recurrence past 12 month 1 recurrence past 6 month Currently take suppressive herpes antiviral therapy Females pregnant , breast feeding planning become pregnant study History allergy famciclovir similar product ( e.g . aciclovir , valaciclovir ) Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>genital herpes</keyword>
	<keyword>herpes</keyword>
	<keyword>famciclovir</keyword>
</DOC>